We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Memorial Sloan Kettering Cancer Center Partners with Quest Diagnostics

By LabMedica International staff writers
Posted on 10 Jun 2014
Print article
Memorial Sloan Kettering Cancer Center (MSK; New York, NY, USA) and Quest Diagnostics (New Jersey, NY, USA), a provider of diagnostic information services, have entered into joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors. Their goal is to use molecular laboratory testing to improve physicians' ability to treat patients with breast, prostate, colon, lung, and a variety of other solid tumor cancers by giving them a better understanding of the genomic underpinnings of their patients' illnesses.

Certain gene mutations influence the efficacy of cancer drug therapies, and a therapy that is effective for one type of cancer may be effective for other types that share the same gene mutations. MSK has amassed extensive databases of gene mutations linked to various types of cancer and developed pharmaceutical treatments based on scientific literature, treatment of patients by the institution's multidisciplinary teams, and clinical trials conducted by MSK researchers and scientists.

Quest's OncoVantage test is performed on tumor biopsies and uses next-generation sequencing technology to assess the most commonly mutated exons in 34 genes. The sequencing data, in de-identified form, will be shared with MSK, which will leverage its databases to correlate specific gene mutations to potential therapies and disease progression applicable to that cancer type.

The second phase of the collaboration between Quest and MSK will involve development of a more far-reaching test by Quest involving potentially hundreds of genes. The expanded test is expected to launch by the spring of 2015.

MSK will provide contextual information about individual mutations identified as part of Quest's OncoVantage, an independently validated, lab-developed test that enables molecular characterization of solid tumors. Beginning this summer (of 2014) physicians who order OncoVantage will benefit from the MSK data through a co-branded clinical annotation report designed to aid the assessment of a patient's prognosis, as well as to guide treatment selection and to monitor disease progression.

Over time, the two organizations intend to further study and extend the mutation data sets to potentially generate improved diagnostics, in addition to research and clinical trials.

MSK has amassed extensive experience in this area over the past decade and has recently developed a pioneering test—called MSK-IMPACT, or Integrated Mutation Profiling of Actionable Cancer Targets—that can reliably and accurately screen for mutations in more than 340 genes. Tumors from MSK patients studied thus far have had on average between two and 10 potentially actionable mutations.

In addition, MSK's clinical annotation process will be enhanced by de-identified gene data from Quest's OncoVantage test. The data will be used to extend the range of information used to assess the clinical significance of gene alterations and potential correlations with therapeutic response.

Craig B. Thompson, MD, MSK's president and CEO said, "This relationship will empower clinicians to improve their patients' health by identifying the best therapies for patients today and by identifying specific patients who may benefit from participation in clinical trials. The needs of tomorrow's patients will be addressed by the deeper knowledge base we are building and its potential to drive the basic science needed to discover new therapies.''

Memorial Sloan Kettering Cancer Center, a private cancer center, is home to more than 12,000 physicians, scientists, nurses, and staff united by dedication to conquering cancer.

Quest Diagnostics provides diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic information services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff.

Related Links:

Memorial Sloan Kettering Cancer Center
Quest Diagnostics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.